Skip to content

ADMA Biologics ADMA Issuance of warrants

Issuance of warrants at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.52M-75.7%
ADMA Biologics logo
ADMA BiologicsADMA
$1.4M
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$409.25K
Applied Digital logo
Applied DigitalAPLD
$121.2M+232%
KEE
Keel Infrastructure Corp. Common StockKEEL
$11.48M
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.52M-75.7%

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued.

The official record: ADMA Biologics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's issuance of warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's issuance of warrants?
ADMA Biologics (ADMA) reported issuance of warrants of $1.4M in Q4 2023.
What does issuance of warrants mean?
This represents changes to additional paid-in capital resulting from the issuance of warrants. It reflects the equity impact of granting rights to purchase shares at a future date, often used as part of financing or incentive arrangements.